Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ADAM POLYNUCLEOTIDES AND POLYPEPTIDES
Document Type and Number:
WIPO Patent Application WO/2000/073323
Kind Code:
A2
Abstract:
The present invention relates to novel human ADAM polypeptides and isolated nucleic acids containing the coding regions of the genes encoding such polypeptides. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human ADAM polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human ADAM polypeptides.

Inventors:
RUBEN STEVEN M (US)
WEI PING (US)
NI JIAN (US)
HASTINGS GREGG A (US)
SHI YANGGU (US)
Application Number:
PCT/US2000/014308
Publication Date:
December 07, 2000
Filing Date:
May 25, 2000
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
HUMAN GENOME SCIENCES INC (US)
RUBEN STEVEN M (US)
WEI PING (US)
NI JIAN (US)
HASTINGS GREGG A (US)
SHI YANGGU (US)
International Classes:
G01N33/50; A61K31/7088; A61K38/00; A61K39/395; A61K45/00; A61K48/00; A61P7/00; A61P9/08; A61P9/10; A61P17/00; A61P25/00; A61P31/00; A61P35/00; A61P37/02; A61P43/00; C07K16/40; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N9/64; C12N15/09; G01N33/15; G01N33/53; G01N37/00; (IPC1-7): C07K/
Domestic Patent References:
WO1997009420A21997-03-13
WO1997031109A11997-08-28
Foreign References:
US5883241A1999-03-16
Other References:
YAGAMI-HIROMASA T. ET AL.: 'A metalloprotease-disintegrin participating in myoblast fusion' NATURE vol. 377, 19 October 1995, pages 652 - 656, XP002934440
INOUE D. ET AL.: 'Cloning and initial characterization of mouse meltrin beta and analysis of the expression of four metalloprotease-disintegrins in bone cells' THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 7, 13 February 1998, pages 4180 - 4187, XP002934441
See also references of EP 1183344A2
Attorney, Agent or Firm:
Hoover, Kenley K. (Inc. 9410 Key West Avenue Rockville, MD, US)
Download PDF:
Claims:
What Is Claimed Is :
1. l.
2. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of: (a) the polynucleotide shown as SEQ ID NO: X or the polynucleotide encoded by a cDNA included in ATCC Deposit No: Z; (b) a polynucleotide encoding a biologically active polypeptide fragment of SEQ ID NO: Y or a biologically active polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No: Z; (c) a polynucleotide encoding a polypeptide epitope of SEQ ID NO: Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z; (d) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a) (c), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.
3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding a soluble polypeptide.
4. The isolated nucleic acid molecule of claim l, wherein the polynucleotide comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO: Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No: Z.
5. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises the entire nucleotide sequence of SEQ ID NO: X or a cDNA included in ATCC Deposit No: Z..
6. The isolated nucleic acid molecule of claim 2, wherein the polynucleotide is DNA.
7. The isolated nucleic acid molecule of claim 3, wherein the polynucleotide is RNA.
8. A vector comprising the isolated nucleic acid molecule of claim 1.
9. A host cell comprising the vector of claim 7.
10. A recombinant host cell comprising the nucleic acid molecule of claim 1 operably limited to a heterologous regulating element which controls gene expression.
11. A method of producing a polypeptide comprising expressing the encoded polypeptide from the host cell of claim 9 and recovering said polypeptide.
12. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of: (a) the polypeptide shown as SEQ ID NO: Y or the polypeptide encoded by the cDNA; (b) a polypeptide fragment of SEQ ID NO: Y or the polypeptide encoded by the cDNA : (c) a polypeptide epitope of SEQ ID NO: Y or the polypeptide encoded by the cDNA; and (d) a variant of SEQ ID NO: Y.
13. The isolated polypeptide of claim 11, comprising a polypeptide having SEQ ID NO: Y.
14. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.
15. A recombinant host cell that expresses the isolated polypeptide of claim 11.
16. A method of making an isolated polypeptide comprising: (a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and (b) recovering said polypeptide.
17. The polypeptide produced by claim 15.
18. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.
19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or absence of a mutation in the polynucleotide of claim 1 ; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.
20. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising: (a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.
21. A method for identifying a binding partner to the polypeptide of claim 11 comprising: (a) contacting the polypeptide of claim 11 with a binding partner; and (b) determining whether the binding partner effects an activity of the polypeptide.
22. A method of screening for molecules which modify activities of the polypeptide of claim 11 comprising: (a) contacting said polypeptide with a compound suspected of having agonist or antagonist activity; and (a) assaying for activity of said polypeptide.
Description:
INTERNATIONALSEARCHREPORTInternationalapplicationNo. PCT/USOO/14308 C(Continuation).DOCUMENTSCONSIDEREDTOBERELEVANT Category*Citationofdocument,withindication,whereappropriate, oftherelevantpassagesRelevanttoclaimNo. XWO97/31109A1(MOCHIDAPHARMACEUTICALCO.,1,2,5-11and13- LTD.)28August1997,pages3-65andFigs.3and17.21 XUS5,883,241A(DOCHERTY et al)16March1999,cols.2-101,2,5-11and13- andSEQIDsNOs:1-4.21 INTERNATIONALSEARCHREPORTInternationalapplicationNo. PCT/US00/14308 BoxIObservationswherecertainclaimswerefoundunsearchable(Cont inuationofitem1offirstsheet) Thisinternationalreporthasnotbeenestablishedinrespectofcerta inclaimsunderArticle17(2)(a)forthefollowingreasons: 1. ClaimsNos.: becausetheyrelatetosubjectmatternotrequiredtobesearchedbythi sAuthority,namely: 2.ClaimsNos.: becausetheyrelatetopartsoftheinternational applicationthatdonotcomplywiththeprescribedrequirementstosuc h anextentthatnomeaningfulinternationalsearchcanbecarriedout,s pecifically: 3.ClaimsNos.: becausetheyaredependentclaimsandarenotdraftedinaccordancewit hthesecondandthirdsentencesofRule6.4(a). Box IIObservationswhereunityofinventionislacking(Continuationofi tem2offirstsheet) ThisInternationalSearchingAuthorityfoundmultipleinventionsin thisinternationalapplication,asfollows: PleaseSeeExtraSheet. 1.ttAsallrequiredadditionalsearchfeesweretimelypaidbytheappl icant,thisinternationalsearchreportcoversallsearchable claims. 2.jAsallsearchableclaimscouldbesearchedwithouteffortjustifyi nganadditionalfee,thisAuthoritydidnotinvitepayment ofanyadditionalfee. 3.Asonlysomeoftherequiredadditionalsearchfeesweretimelypaidb ytheapplicant,thisinternationalsearchreportcovers onlythoseclaimsforwhichfeeswerepaid,specificallyclaimsNos.: 4.!Norequiredadditionalsearchfeesweretimelypaidbytheapplican t.Consequently,thisinternationalsearchreportis restrictedtotheinventionfirstmentionedintheclaims;itiscovere dbyclaimsNos.: 1-12&14-21,thespeciesofSEQIDNO:9 RemarkonProtestTheadditionalsearchfeeswereaccompaniedbytheap plicant'sprotest. No protestaccompaniedthepaymentofadditionalsearchfees. INTERNATIONALSEARCHREPORTInternationalapplicationNo. PCT/US00/14308 BOXII.OBSERVATIONSWHEREUNITYOFINVENTIONWASLACKING ThisISAfoundmultipleinventionsasfollows : Thisapplicationcontainsthefollowinginventionsorgroupsofinven tionswhicharenotsolinkedastoforma singleinventiveconceptunderPCTRule13.1.Inorderforallinventio nstobesearched,theappropriateadditional searchfeesmustbepaid. GroupIincludesatleastsixindependentspeciesofclaims1-12and14- 21,drawntoafirstproduct,an isolatedproteaseorfragmentthereof,toafirstmethodofmakingthep roteaseutilizinganucleicacidencodingallor partofprotease,aswellastovectorsandhostcellscomprisingthenuc leicacid,andtoafirstmethodofuseofthe polypeptideproduct,orafirstmethodofuseofitsencodingnucleicac id,intreatmentordiagnosisofmedical conditions;furthermethodsofuseofthepolypeptideinassaysforide ntifyingbindingpartnersandactivitymodulators arealsoincluded. Group11includesatleastsixindependentspeciesofclaims1-11,16,1 7,19and20,drawntoafirstsecond product,anepitopeofapolypeptide,toafirstmethodofmakingtheepi topeutilizinganucleicacidencodingan epitope,andtomethodsofuseoftheepitopeintreatmentordiagnosiso fmedicalconditions;furthermethodsofuseof theepitopeinassaysforidentifyingbindingpartnersarealsoinclud ed. GroupIIIincludesatleastsixindependentspeciesofclaim13,drawnt oathirdproduct,anantibody. Thisapplicationcontainsclaimsdirectedtomorethanonespeciesoft hegenericinvention.Thesespeciesare deemedtolackUnityofInventionbecausetheyarenotsolinkedastofor masingleinventiveconceptunderPCTRule 13.1.Inorderformorethanonespeciestobesearched,theappropriate additionalsearchfeesmustbepaid.The speciesareasfollows: InGroupIthereareatleastsixspeciesofpolypeptideshavingaminoac idsequencesofSEQIDsNOs:9-14in TableIofthespecificationencodedbytheircorrespondingnucleicac idspeciesenumeratedasSEQIDsNOs:2-7 accordingtoTableIofthespecification.Theclaimsareconsideredto correspondtothespecieslistedaboveinthe followingmanner:Claim1'sclauses(a),(b)and(d)describeprotease shavingaminoacidsequencesofSEQIDs NOs:9-14encodedbythecorrespondingnucleicacidshavingsequences representedinSEQIDsNOs:2-7.Eachof claims1-12and14-21isgeneric. InGroupIIthereareatleastsixspeciesofpeptideorpolypeptideepit opesconstitutingundesignatedregions withinanyoftheproteasesofSEQIDsNOs:9-14accordingtoTableIofth especificationencodedbycorresponding nucleicacidsequenceregionswithinanyofSEQIDsNOs:2-7.Theclaims aredeemedtocorrespondtothespecies listedaboveinthefollowingmanner:Clause(c)ofclaim1whereinapep tideorpolypeptideepitopeconstitutesan undesignatedaminoacidsequencesomewherewithinanyofSEQIDsNOs:9 -14encodedbyacorresponding, undesignated,nucleicacidsequencesomewherewithinanyofSEQIDsNO s:2-7.Thefollowingclaimsaregeneric: Eachofclaims1-10isgeneric. InGroupIIIthereareatleastsixspeciesofantibodiescapableofreco gnizinganyoftheproteasesenumerated inTableIofthespecificationasSEQIDsNOs:9-14.Theclaimsaredeeme dtocorrespondtothespecieslistedabove inthefollowingmanner:Claim13embracesantibodiesthatwillbindto anyoftheproteasesofSEQIDsNOs:9-14, thusisagenericclaim. TheinventionslistedasGroups1,11,andIIIdonotrelatetoasinglein ventiveconceptunderPCTRule13.1 because,underPCTRule13.2,theylackthesameorcorrespondingspeci altechnicalfeaturesforthefollowingreasons: TheinventionofGroupIlacksasameorcorrespondingtechnicalfeatur ewiththeinventionofGroup11 becauseneitherapeptidenorapolypeptideofGroupIlneedhavinganyv estigeofproteolyticactivity,whichactivityis disclosedtobeaspecialtechnicalfeatureofGroupI.Theinventionof GroupIlacksasameorspecialtechnical featurewithaninventionofGroup111becausetheinventionofGroup11 1,anantibody,hasneitherastructuralnora functionalrelationshiptoaproteaseofGroupIthuscannotshareeith erasame,noracorresponding,noraspecial technicalfeaturewithaninventionofGroup1. TheinventionofGroupIIlacksasameorcorrespondingtechnicalfeatu rewiththeinventionofGroupIII becausetheinventionofGroup111,anantibody,hasneitherastructur alnorafunctionalrelationshiptoanepitopeof Group1Ithuscannotshareeitherasame,noracorresponding,noraspec ialtechnicalfeaturewithaninventionof Group11. Thespecieslistedabove,representedatleastbytheaminoacidsequen cesofthesixidentifieproteasesof SEQIDsNOs:9-14andbythemuchmorenumerousaminoacidsequencesofth eundesignatedepitopes,donotrelate toasingleinventiveconceptunderPCTRule13.1because,underPCTRul e13.2,thespecieslackthesameor correspondingspecialtechnicalfeaturesforthefollowingreasons: Eachspeciesrepresentsaproteaseoranepitope whichisnotrequiredto,andhasnoclear,structuralorotherrelation shipwithanotherproteaseorepitopesince,as disclosed,eachprotease,orportionthereof,isadistinctgeneprodu ct,thereforeshareonlyageneric,ratherthana INTERNATIONALSEARCHREPORTInternationalapplicationNo. PCT/US00/14308 special,technicalfeature.